Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial

BACKGROUND/AIMS: Intestinal Behçet's disease (BD) is an immune-mediated inflammatory disorder. We followed up the patients and evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through 100 weeks rolled over from the 52 week clinical trial (NCT01243671)....

Full description

Saved in:
Bibliographic Details
Published in:Intest Res
Main Authors: Inoue, Nagamu, Kobayashi, Kiyonori, Naganuma, Makoto, Hirai, Fumihito, Ozawa, Morio, Arikan, Dilek, Huang, Bidan, Robinson, Anne M., Thakkar, Roopal B., Hibi, Toshifumi
Format: Artigo
Language:Inglês
Published: Korean Association for the Study of Intestinal Diseases 2017
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5478765/
https://ncbi.nlm.nih.gov/pubmed/28670237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2017.15.3.395
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items